- Home
- LCTX vs NBH Comparison
LCTX vs NBH Comparison
Compare LCTX & NBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- NBH
- Stock Information
- Founded
- LCTX 1990
- NBH 2002
- Country
- LCTX United States
- NBH United States
- Employees
- LCTX N/A
- NBH N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- NBH Finance/Investors Services
- Sector
- LCTX Health Care
- NBH Finance
- Exchange
- LCTX Nasdaq
- NBH Nasdaq
- Market Cap
- LCTX 274.0M
- NBH 292.3M
- IPO Year
- LCTX N/A
- NBH N/A
- Fundamental
- Price
- LCTX $1.21
- NBH $9.87
- Analyst Decision
- LCTX Strong Buy
- NBH
- Analyst Count
- LCTX 4
- NBH 0
- Target Price
- LCTX $4.25
- NBH N/A
- AVG Volume (30 Days)
- LCTX 1.5M
- NBH 85.9K
- Earning Date
- LCTX 08-12-2025
- NBH 01-01-0001
- Dividend Yield
- LCTX N/A
- NBH 4.34%
- EPS Growth
- LCTX N/A
- NBH N/A
- EPS
- LCTX N/A
- NBH 0.12
- Revenue
- LCTX $10,914,000.00
- NBH N/A
- Revenue This Year
- LCTX N/A
- NBH N/A
- Revenue Next Year
- LCTX $178.80
- NBH N/A
- P/E Ratio
- LCTX N/A
- NBH $87.04
- Revenue Growth
- LCTX 76.43
- NBH N/A
- 52 Week Low
- LCTX $0.37
- NBH $8.75
- 52 Week High
- LCTX $1.31
- NBH $11.01
- Technical
- Relative Strength Index (RSI)
- LCTX 59.58
- NBH 51.66
- Support Level
- LCTX $1.15
- NBH $9.76
- Resistance Level
- LCTX $1.31
- NBH $9.94
- Average True Range (ATR)
- LCTX 0.08
- NBH 0.09
- MACD
- LCTX 0.01
- NBH 0.00
- Stochastic Oscillator
- LCTX 70.59
- NBH 55.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.